Abstract submission

Submit your abstract now

Abstract submission is an important part of this meeting. 

As a participant, you’ll have the opportunity to submit an abstract and (if it’s accepted) have the possibility to discuss it with the international faculty and your peers. 

Submitting an abstract constitutes a formal commitment to attend the meeting in Lisbon, Portugal (should the abstract be accepted). If requested, you must also present the work as an oral or poster presentation during the assigned session and time slot in the scientific program. 

Registration

All other authors who wish to take advantage of the early bird registration fee should complete their registration before December 9, 2026 (23:59 CET). 

For further details, visit our registration page.

Submission procedure

The abstracts / clinical cases submitted via the submission portal will be reviewed and allocated by the Scientific Program Committee.

Regular abstract/clinical case submission

  • July 1, 2026: Open submission
  • November 14, 2026 (23:59 CET): Deadline submission
  • By December 1, 2026: Notification of allocation
  • December 15, 2026: Withdrawal deadline

Late-breaker abstract/clinical case submission

This is an opportunity to submit groundbreaking, high-impact research with recent, time-sensitive data that could not have been available during the regular submission period.

It is not intended for work delayed due to time constraints, but for studies with the potential to significantly influence practice or advance science.

The terms & conditions will be published closer to the submission.

  • January 1, 2027: Open Late-breaker submission
  • January 8, 2027 (23:59 CET): Deadline Late-breaker submission
  • By January 18, 2027: Notification of allocation

Guidelines for abstract/clinical case submission

Before you submit an abstract, you should read the following guidelines. 

  • Title count: max. 300 characters incl. space. 
  • Character limit: 3500 characters (incl. spaces & punctuation and headers in the template). 
  • Please use the following subheadings: Background / Aims / Methods / Results / Summary – Conclusion 
  • Images have to be submitted as JPEG, tif, or gif files:   
    • Due to limited space, only a simple graph/image can be submitted; 
    • Images and graphs should reproduce well in black and white; 
    • Image file should not exceed 500KB. 
  • Authors: There is no limit to the number of authors. 
  • References are obligatory when submitting an abstract or clinical case. 

Abstract and clinical case submission topics

Please select the most appropriate topic during the abstract and case submission: 

CAR-based Cellular Therapy – Clinical​ 

  • Biomarkers for CAR T efficacy and prediction model for response and toxicity​
  • Challenges of CAR-based cellular therapy (bridging therapies and lymphodepletion), and clinical indication​ 
  • Clinical investigations into therapeutic applications of CAR-T cell in oncology and other fields, adult/pediatric indications​ 
  • Management of toxicities (early and late)​ 

CAR-based Cellular Therapy – Preclinical​ 

  • CAR T cell manufacturing methodologies​ 
  • Innovative T cell engineering, CAR designs, and optimization of CAR T cell function​ 
  • Mechanistic studies of CAR T efficacy and toxicities, and tumor resistance​ 
  • Novel in vivo and in vitro models to functionally evaluate CAR T cells​ 

Clinical cases​ 

  • Clinical case on multiple myeloma​ 
  • Clinical case on new technologies for CAR T development​ 
  • Clinical case on solid tumors​ 

Other​ 

  • Access to CAR T​ 
  • Advanced Practice Roles within the Multidisciplinary team in CAR T Therapy​ 
  • Models of Care and Multidisciplinary Collaboration in CAR T Programs​ 
  • Perspectives in Adolescent and Young Adult (AYA) CAR T Care​ 
  • Quality of Life​ 
  • Real-world Nursing Practice in CAR T-cell Therapy​
  • Symptom Management and Toxicity Monitoring in CAR T Patients​ 
Share